

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: PD01059K Q	SERIAL NO.: TO BE ASSIGNED
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: WING-KEE PHILIP CHO	
		FILING DATE: 11/03/2002	GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
/HS/	AA 6,521,254 B2	02/18/2003	Weinstein, et al	424	468	
	AB 6,514,520 B2	02/04/2003	Munayyer, et al	424	439	
	AC 6,506,767 B1	01/14/2003	Schumacher, et al	514	290	
	AD 6,132,758	10/17/2000	Munayyer, et al	424	439	
	AE 6,100,274	08/08/2000	Kou	514	290	
	AF 6,051,585	04/18/2000	Weinstein, et al	514	335	
	AG 5,939,426	08/17/1999	McCullough	514	290	
	AH 5,900,421	05/04/1999	Handley, et al.	514	290	
	AI 5,731,319	03/24/1998	Aberg, et al.	514	290	
	AJ 5,595,997	01/21/1997	Aberg, et al.	514	290	
	AK 5,476,856	12/19/1995	Carceller, et al	514	290	
	AL 5,407,941	04/18/1995	Carceller, et al	514	290	
	AM 5,314,697	05/24/1994	Kwan, et al.	424	480	
	AN 5,100,675	03/31/1992	Cho, et al.	424	468	
	AO 5,089,496	02/18/1992	Piwinski, et al.	514	253	
	AP 5,019,591	05/28/1991	Gardner, et al.	514	461	
	AQ 4,990,535	02/05/1991	Cho, et al.	514	556	
	AR 4,906,647	03/06/1990	Kouchiwa, et al	514	356	
	AS 4,863,931	09/05/1989	Schumacher, et al.	514	290	
	AT 6,270,796 B1	08/07/2001	Weinstein, et al	424	457	
/HS/	AU 4,804,666	02/14/1989	Piwinski, et al..	514	278	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
/HS/	AV 0 264 259 A1	04/20/1988	European Patent Office	A 61 K	31/44	
	AW 0 288,640 A1	11/02/1988	European Patent Office	A61K	31/445	
	AX 0 396,404 A1	11/07/1990	European Patent Office	A61K	31/445	
	AY 0 396,404 B1	02/16/1994	European Patent Office	A61K	31/445	
	AZ 0 577 957 A1	01/12/1994	European Patent Office	C07D	401/00	
/HS/	BA WO 85/03707	08/29/1985	WIPO			
/HS/	BB WO 92/00293	01/09/1992	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/HS/	BC	Andersen, et al., "Adverse drug interactions clinically important for the dermatologist", Arch Dermatol, April, 1995, Vol.131, pp. 468-473.
/HS/	BD	Babe, et al., "Histamine, Bradykinn, and their Antagonists" in The Pharmacological Basis of Therapeutics (9th edition), The McGraw-Hill Co. Inc., pp. 581-599 (1996).
/HS/	BE	Barnett, et al., "Pharmacology of Non-Sedating H1 Antihistamines", New Perspectives in Histamine Research, Birkhauser Verlag Basel, pp. 181-196 (1991).

EXAMINER /Humera Sheikh/	DATE CONSIDERED 07/26/2007
-----------------------------	-------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: PD01059KQ	SERIAL NO.: TO BE ASSIGNED	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Wing-Kee Philip Cho		
(Use several sheets if necessary)				FILING DATE: 11/03/2003		GROUP: 1615

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
/HS/	BF 4,783,465	11/08/1988	Sunshine, et al.	514	255		
	BG 4,777,170	10/11/1988	Heinrich	514	226.2		
	BH 4,731,447	03/15/1988	Schumacher, et al.	546	93		
	BI 4,659,716	04/21/1987	Villani, et al.	514	290		
	BJ 4,552,899	11/12/1985	Sunshine, et al.	514	568		
	BK 4,371,516	02/01/1983	Gregory, et al.	424	22		
	BL 4,282,233	08/04/1981	Vilani	424	267		
	BM 4,008,796	02/22/1977	Aylon	198	460		
	BN 3,940,485	02/24/1976	Levinson, et al.	424	250		
	BO 3,916,899	11/04/1975	Theeuwes, et al.	128	260		
	BP 3,845,770	11/05/1974	Theeuwes, et al.	128	260		

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
BQ WO 92/11034	07/09/1992	WIPO			YES	NO	
BR WO 92/20377	11/26/1992	WIPO					
BS WO 96/20708	07/11/1996	WIPO					
BT WO 96/16641	06/06/1996	WIPO					
BU WO 98/34614	08/13/1998	WIPO					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
/HS/	BV Berge, et al., "Pharmaceutical Salts", J. of Pharm. Sciences, January, 1977, Vol. 66, No.1, pp. 1-19.
/HS/	BW Berthon, et al., "In Vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3)", Biochem. Pharm., 1994, Vol. 47, No.5, pp. 789-794.
/HS/	BX Blaug, et al., "Interaction of dextroamphetamine sulfate with spray-dried lactose", J. of Pharm. Sciences, November, 1972, Vol. 61, No.11, pp. 1770-1775.
/HS/	BY Brandes, et al., "Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates", J. of the National Cancer Inst., May 18, 1994, Vol. 86, No.10, pp. 770-775.
/HS/	BZ Brandes, et al., "Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses", Cancer Research, July 1, 1992, Vol. 52, pp. 3796-3800.

EXAMINER /Humera Sheikh/	DATE CONSIDERED 07/26/2007
---------------------------------	-----------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
Wing-Kee Philip ChoFILING DATE
11/03/2003GROUP:
1615

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
/HS/	CA 3,598,123	08/10/1971	Zaffaroni	128	268	
/HS/	CB 3,536,809	10/27/1970	Appelzweig	424	28	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
/HS/	CC WO 00/2560	01/20/2000	PCT International			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/HS/	CD	Brion, et al., "Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers", Br. J. Clin. Pharmacol. 1988, Vol. 25, pp.27-32.
	CE	Carmeliet, "Voltage- and Time-Dependent Block of the Delayed K ⁺ Current in Cardiac Myocytes by Dofetilide", The J. of Pharm. And Experimental Therapeutics, 1992, Vol. 262, No. 2, pp. 809-817.
	CF	Castello, et al., "Discoloration of tablets containing amines and lactose", J. of Pharm. Sciences, February, 1962, Vol. 51, No.2, pp. 106-108.
	CG	Cheung, et al., "Investigation of anti-motion sickness drugs in the squirrel monkey", J. Clin. Pharmacol, 1992, Vol. No. 32, pp. 163-175.
	CH	Clissold, et al., "Loratadine: A preliminary review of its pharmacodynamic properties and therapeutic efficacy", Drugs, 1989, Vol. 37, pp. 42-57.
	CI	Cooke, "Glycopyrrolate in bladder dysfunction", SA Medical Journal, January 1, 1983, p. 3.
	CJ	Craft, "Torsade de pointes after astemizole overdose", Br. Medical Journal, 1986,, Vol. 292, p. 660.
	CK	Dorje, et al., "Antagonist Binding Profiles of Five Cloned Human Muscarinic Receptor Subtypes", The J. of Pharm. And Experimental Therapeutics, 1991, Vol. 256, pp. 727-733.
	CL	Drug Facts and Comparisons, 1998 Ed., Facts and Comparisons, St. Louis, Missouri, p. 2832.
	CM	Ebert, "Soft elastic gelatin capsules: a unique dosage form", Pharmaceutical Technology, 1977, p. 44-50.
	CN	Gengo, "Dilemma: Antihistamine selection: Use vs. Side effects", U.S. Pharmacist, November, 1990, pp. 59-92.
	CO	Hartauer, et al., A Comparison of Diffuse Reflectance FT-IR Spectroscopy and DSC in the Characterization of a Drug-Excipient Interaction, "Drug Development and Industrial Pharmacy", 1991, Vol. 17, No. 4, pp. 617-630.
	CP	Herron, et al., "Dose Proportionality, Linearity, and Pharmacokinetics of Desloratadine in Healthy Volunteers" (Abstract 1126), J. Allergy Clin. Immunol., January, 2000, Vol. 105, No. 1, Part 2, p. S385.
	CQ	Herzog, et al., "Urinary Incontinence: medical and Psychosocial Aspects", Annual Review of Gerontology and Geriatrics, 1989, Vol. 9, pp. 74-119.
	CR	Hilbert, et al., "Pharmacokinetics and Dose Proportionality of Loratadine", J. Clin. Pharmacol. 1987, Vol. 27, pp. 694-98.
	CS	Housley, et al., "Histamine and related substances influence neurotransmission in the semicircular canal", Hearing Research, May 1, 1988, Vol. 35, pp. 87-97.
	CT	Jankowski, et al., "Effect of Terfenadine on Nnasal Provocation", Int. Arch. Allergy Immunolog., 1993, Vol. 101, pp. 311-317.
	CU	Kaliner, "Nonsteroidal Antihistamines: Pharmacology, Clinical Efficacy and Adverse Effects", American Family Physician, March, 1992, Vol. 45, No. 3, pp.1337-1342.
	CV	Kleine-Tebbe, et al., "Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine", J. Allergy Clin. Immunol., 1994, Vol. 93, pp. 494-500.
/HS/	CW	Knowles, "Astemizole and Terfenadine-Induced Cardiovascular Effects", The Canadian J. of Hospital Pharmacy, February, 1992, Vol. 45, No. 1, pp. 33 & 37.

EXAMINER

DATE CONSIDERED

/Humera Sheikh/

07/26/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /HS/

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: PD01059KQ		SERIAL NO.: TO BE ASSIGNED	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Wing-Kee Philip Cho			
(Use several sheets if necessary)				FILING DATE: 11/03/2003		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
/HS/	DM	Nelemans, "Antiallergic and antitussive drugs", <u>Side Effects of Drugs Annual 12</u> , Elsevier Science Publishers B.V., 1988, pp. 144-147.					
	DN	Nomeir, et al., "Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from Extended-Release Tablets in Healthy Volunteers", <u>J. Clin. Pharm.</u> , 1996, Vol. 36, No. 10, pp. 923-930.					
	DO	Padhi, et al., "Multiple-Dose Pharmacokinetics; Safety and Tolerance of Desloratadine in Healthy Volunteers (Abstract 1124), January, 2000, <u>J. Allergy Clin. Immunol.</u> , January, 2000, Vol. 105, No. 1, part 2, p. S385.					
	DP	Parkinson, et al., "Evaluation of Loratadine as an Inducer of Liver Microsomal Cytochrome P450 in Rats and Mice", <u>Biochemical Pharmacology</u> , 1992, Vol. 43, No. 10, pp. 2169-2180.					
	DQ	Peggs, et al., "Antihistamines: The Old and the New", <u>American Family Physician</u> , August, 1995, Vol. 52, No. 2, pp. 593-600.					
	DR	Petrin, "Bewegungskrankheit und ihre Therapie/ Eine Übersicht (Motion Sickness and its Treatment)", <u>Schweiz, Rundschau Med.</u> , 1974, (PRAXIS) 63, pp. 79-81.					
	DS	Quercia, et al., "Focus on Loratadine: A new second-generation non-sedating H1-receptor antagonist", <u>Hosp. Formul.</u> , February 1993, Vol. 28, pp. 137, 138, 141, 142, 144, 149, & 153.					
	DT	Remington's Pharmaceutical Sciences. 18th Ed, Alfonso R. Gennaro, Mack Publishing Company, Easton, PA, 1990, pp. 1519-1520.					
	DU	Remington's Pharmaceutical Sciences. 18th Ed, Alfonso R. Gennaro, Mack Publishing Company, Easton, PA, 1990, pp. 1527-1529					
	DV	Resnick, "Urinary incontinence", <u>The Lancet</u> , July 8, 1995, Vol. 346, pp. 94-99.					
	DW	Roman, et al., "Loratadine-A Review of Recent Finding in Pharmacology Pharmacokinetics, Efficacy, and Safety, with a Look at its Use in Combination with Pseudoephedrine", <u>Clin. Reviews in Allergy</u> , 1993, Vol. 11, pp. 89-110.					
	DX	Salmun, et al., "Efficacy and Safety of Desloratadine in Seasonal Allergic Rhinitis, January, 2000, <u>J. Allergy Clin. Immunol.</u> (Abstract 1123), Vol. 105, No. 1, Part 2, pp. S384-S385.					
	DY	Simons, "H1-Receptor Antagonists Comparative Tolerability and Safety", <u>Drug Safety</u> , 1994, Vol. 10, No. 5, pp. 350-380					
	DZ	Sunahara, et al., "Pharmacological interventions for motion sickness: Cardiovascular Effects", <u>Aviation, Space and Environmental Medicine</u> , September, 1987, pp. A270-A276.					
	EA	Temple, et al., "Loratadine, an Antihistamine, Blocks Antigen- and Ionophore-Induced Leukotriene Release from Human Lung In Vitro", <u>Prostaglandins</u> , 4/1988, 35(4):549-554.					
	EB	Van Cauwenberge, "New Data on the Safety of Loratadine", <u>Drug Invest.</u> , 1992, Vol. 4, No. 4, pp.283-291.					
	EC	Van Peer, et al., "Ketoconazole Inhibits Loratadine Metabolism in Man", <u>Beerse, Belgium, Abstract 1234</u> , p. 34.					
/HS/	ED	Wade, et al., <u>Handbook of Pharmaceutical Excipients</u> (2 nd edition), American Pharmaceutical Association and Pharma Press, Royal Pharma. Society of G. Britain, 1994, pp. 257&259.					
EXAMINER	/Humera Sheikh/			DATE CONSIDERED 07/26/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

